Suppr超能文献

干扰素调节因子 1(IRF-1)通过 CXCL10/CXCR3 轴在肝细胞癌(HCC)中激活抗肿瘤免疫。

Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC).

机构信息

Department of General Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530007, China; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 15260, USA.

Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 15260, USA; Department of Rheumatology and Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.

出版信息

Cancer Lett. 2021 May 28;506:95-106. doi: 10.1016/j.canlet.2021.03.002. Epub 2021 Mar 6.

Abstract

Interferon regulatory factor 1 (IRF-1) is a tumor suppressor gene in cancer biology with anti-proliferative and pro-apoptotic effect on cancer cells, however mechanisms of IRF-1 regulating tumor microenvironment (TME) in hepatocellular carcinoma (HCC) remain only partially characterized. Here, we investigated that IRF-1 regulates C-X-C motif chemokine 10 (CXCL10) and chemokine receptor 3 (CXCR3) to activate anti-tumor immunity in HCC. We found that IRF-1 mRNA expression was positively correlated with CXCL10 and CXCR3 through qRT-PCR assay in HCC tumors and in analysis of the TCGA database. IRF-1 response elements were identified in the CXCL10 promoter region, and ChIP-qPCR confirmed IRF-1 binding to promote CXCL10 transcription. IRF-2 is a competitive antagonist for IRF-1 mediated transcriptional effects, and overexpression of IRF-2 decreased basal and IFN-γ induced CXCL10 expression. Although IRF-1 upregulated CXCR3 expression in HCC cells, it inhibited proliferation and exerted pro-apoptotic effects, which overcome proliferation partly mediated by activating the CXCL10/CXCR3 autocrine axis. In vitro and in vivo studies showed that IRF-1 increased CD8 T cells, NK and NKT cells migration, and activated IFN-γ secretion in NK and NKT cells to induce tumor apoptosis through the CXCL10/CXCR3 paracrine axis. Conversely, this effect was markedly abrogated in HCC tumor bearing mice deficient in CXCR3. Therefore, the IRF-1/CXCL10/CXCR3 axis contributes to the anti-tumor microenvironment in HCC.

摘要

干扰素调节因子 1(IRF-1)在癌症生物学中是一种肿瘤抑制基因,对癌细胞具有抗增殖和促凋亡作用,然而,IRF-1 调节肝癌(HCC)肿瘤微环境(TME)的机制仍部分特征不明。在这里,我们研究了 IRF-1 通过调节 C-X-C 基序趋化因子 10(CXCL10)和趋化因子受体 3(CXCR3)来激活 HCC 中的抗肿瘤免疫。我们发现,通过 qRT-PCR 分析 HCC 肿瘤和 TCGA 数据库分析,IRF-1mRNA 表达与 CXCL10 和 CXCR3 呈正相关。在 CXCL10 启动子区域鉴定出 IRF-1 反应元件,ChIP-qPCR 证实 IRF-1 结合以促进 CXCL10 转录。IRF-2 是 IRF-1 介导的转录效应的竞争性拮抗剂,IRF-2 的过表达降低了基础和 IFN-γ 诱导的 CXCL10 表达。尽管 IRF-1 上调 HCC 细胞中 CXCR3 的表达,但它抑制增殖并发挥促凋亡作用,通过激活 CXCL10/CXCR3 自分泌轴部分克服增殖。体外和体内研究表明,IRF-1 增加 CD8 T 细胞、NK 和 NKT 细胞迁移,并激活 NK 和 NKT 细胞中的 IFN-γ 分泌,通过 CXCL10/CXCR3 旁分泌轴诱导肿瘤凋亡。相反,在缺乏 CXCR3 的 HCC 肿瘤荷瘤小鼠中,这种作用明显减弱。因此,IRF-1/CXCL10/CXCR3 轴有助于 HCC 的抗肿瘤微环境。

相似文献

1
Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC).
Cancer Lett. 2021 May 28;506:95-106. doi: 10.1016/j.canlet.2021.03.002. Epub 2021 Mar 6.
3
[Expression and clinical significance of chemokine CXCL10 and its receptor CXCR3 in hepatocellular carcinoma].
Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Jun 18;51(3):402-408. doi: 10.19723/j.issn.1671-167X.2019.03.005.
5
Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Cell Mol Gastroenterol Hepatol. 2018 Sep 11;7(1):115-134. doi: 10.1016/j.jcmgh.2018.08.008. eCollection 2019.
6
Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth.
J Hepatol. 2014 Jan;60(1):103-9. doi: 10.1016/j.jhep.2013.08.017. Epub 2013 Aug 30.
7
Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma.
World J Gastroenterol. 2005 Jan 14;11(2):164-70. doi: 10.3748/wjg.v11.i2.164.
8
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Cancer Immunol Immunother. 2020 Sep;69(9):1891-1903. doi: 10.1007/s00262-020-02586-9. Epub 2020 May 6.
10
Hepatocellular carcinoma and CXCR3 chemokines: a narrative review.
Clin Ter. 2017 Jan-Feb;168(1):e37-e41. doi: 10.7417/CT.2017.1980.

引用本文的文献

1
Association of interferon regulatory factor 8 dysregulation with dry eye in Sjögren's syndrome.
Int J Ophthalmol. 2025 Aug 18;18(8):1456-1463. doi: 10.18240/ijo.2025.08.05. eCollection 2025.
2
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy.
Cell Mol Immunol. 2025 Jun 11. doi: 10.1038/s41423-025-01308-4.
4
The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC.
Front Immunol. 2025 Apr 30;16:1569915. doi: 10.3389/fimmu.2025.1569915. eCollection 2025.
7
Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis.
Signal Transduct Target Ther. 2024 Nov 18;9(1):325. doi: 10.1038/s41392-024-02018-5.
9
The multiple roles of interferon regulatory factor family in health and disease.
Signal Transduct Target Ther. 2024 Oct 9;9(1):282. doi: 10.1038/s41392-024-01980-4.

本文引用的文献

1
CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
Front Immunol. 2020 May 29;11:976. doi: 10.3389/fimmu.2020.00976. eCollection 2020.
2
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
3
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Cancer Immunol Immunother. 2020 Sep;69(9):1891-1903. doi: 10.1007/s00262-020-02586-9. Epub 2020 May 6.
5
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy.
Cancer Immunol Res. 2020 Jul;8(7):952-965. doi: 10.1158/2326-6066.CIR-19-0159. Epub 2020 Apr 7.
6
Tumor Immunology and Tumor Evolution: Intertwined Histories.
Immunity. 2020 Jan 14;52(1):55-81. doi: 10.1016/j.immuni.2019.12.018.
7
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
J Exp Clin Cancer Res. 2019 Nov 4;38(1):447. doi: 10.1186/s13046-019-1412-8.
8
Anti-apoptotic effect by the suppression of IRF1 as a downstream of Wnt/β-catenin signaling in colorectal cancer cells.
Oncogene. 2019 Aug;38(32):6051-6064. doi: 10.1038/s41388-019-0856-9. Epub 2019 Jul 10.
9
IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell.
Cancer Immunol Res. 2019 Aug;7(8):1258-1266. doi: 10.1158/2326-6066.CIR-18-0711. Epub 2019 Jun 25.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验